[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CO6150140A2 - Inhibidores de proteina tirosina fosfatasa humana y metodos de uso - Google Patents

Inhibidores de proteina tirosina fosfatasa humana y metodos de uso

Info

Publication number
CO6150140A2
CO6150140A2 CO09007334A CO09007334A CO6150140A2 CO 6150140 A2 CO6150140 A2 CO 6150140A2 CO 09007334 A CO09007334 A CO 09007334A CO 09007334 A CO09007334 A CO 09007334A CO 6150140 A2 CO6150140 A2 CO 6150140A2
Authority
CO
Colombia
Prior art keywords
substituted
unsubstituted
branched
alkyl
linear
Prior art date
Application number
CO09007334A
Other languages
English (en)
Inventor
Jeffrey Lyle Gray
Mathew Brian Maier
Ryan Nichols
Kande Amarasighe
Cynthia Clark
Original Assignee
Procter & Gamble & Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & Gamble & Company filed Critical Procter & Gamble & Company
Publication of CO6150140A2 publication Critical patent/CO6150140A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/28—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Reproductive Health (AREA)
  • AIDS & HIV (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)

Abstract

1.- Un compuesto que tiene la fórmula:en donde R es una unidad tiazolilo sustituida o no sustituida que tiene la fórmula:R2 y R3 se escogen cada uno independientemente de:hidrógeno; ii) alquilo C1-C6 lineal, ramificado o cíclico sustituido o no sustituido; iii) fenilo sustituido o no sustituido; iv) heteroarilo sustituido o no sustituido; o R2 y R3 se pueden tomar juntos para formar un anillo saturado o insaturado que tiene de 5 a 7 átomos; dichas sustituciones se escogen independientemente de uno o más unidades alquilo C1-C6 lineal, cíclico o ramificado, halógeno, hidroxilo, o ciano; R4 es una unidad escogida de: i) hidrógeno; ii) alquilo C1-C6 lineal, ramificado o cíclico sustituido o no sustituido; iii) fenilo sustituido o no sustituido; y iv) heteroarilo sustituido o no sustituido; Z es una unidad que tiene la fórmula:R1 se escoge de: i) hidrógeno; ii) alquilo C1-C6 lineal, ramificado o sustituido o no sustituido; iii) arilo sustituido o no sustituido; anillos heterocíclicos sustituidos y no sustituidos; o anillos heteroarilo, sustituidos o no sustituidos; L es una unidad de enlace escogida de: i) -C(O)NH[C(R5aR5b)w-; ii) -C(O)(C(R6aR6b]x-; iii) -C(O)[C(R7aR7b]yC(O)-; iv) -SO2[C(R8aR8b)]z-;R5a, R5b, R6a, R6b, R7a, R7b, R8a, y R8b son cada uno independientemente: i) hidrógeno; ii) alquilo C1-C4 lineal o ramificado sustituido o no sustituido; iiii) arilo sustituido o no sustituido; iv) anillos heterocíclicos sustituidos y no sustituidos; v) anillos heteroarilo sustituidos o no sustituidos; el índice n es 0 o 1; los índices w, x, y, y z son cada uno independientemente de 1 a 4.
CO09007334A 2006-06-27 2009-01-27 Inhibidores de proteina tirosina fosfatasa humana y metodos de uso CO6150140A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US81673006P 2006-06-27 2006-06-27
US81682506P 2006-06-27 2006-06-27
US81673106P 2006-06-27 2006-06-27

Publications (1)

Publication Number Publication Date
CO6150140A2 true CO6150140A2 (es) 2010-04-20

Family

ID=38704715

Family Applications (1)

Application Number Title Priority Date Filing Date
CO09007334A CO6150140A2 (es) 2006-06-27 2009-01-27 Inhibidores de proteina tirosina fosfatasa humana y metodos de uso

Country Status (20)

Country Link
US (3) US7795444B2 (es)
EP (3) EP3293182A1 (es)
JP (6) JP5261383B2 (es)
KR (1) KR101179087B1 (es)
AU (1) AU2007265454B2 (es)
BR (1) BRPI0713357A2 (es)
CA (1) CA2657107C (es)
CO (1) CO6150140A2 (es)
CY (1) CY1116377T1 (es)
DK (1) DK2038265T3 (es)
ES (1) ES2534392T3 (es)
HK (1) HK1129387A1 (es)
HU (1) HUE024976T2 (es)
IL (1) IL196129A (es)
MX (1) MX2009000289A (es)
NZ (1) NZ574406A (es)
PL (1) PL2038265T3 (es)
PT (1) PT2038265E (es)
SI (1) SI2038265T1 (es)
WO (1) WO2008002570A2 (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7226755B1 (en) * 2002-09-25 2007-06-05 The Procter & Gamble Company HPTPbeta as a target in treatment of angiogenesis mediated disorders
US7507568B2 (en) * 2002-09-25 2009-03-24 The Proctor & Gamble Company Three dimensional coordinates of HPTPbeta
AU2007237096C1 (en) * 2006-04-07 2012-12-13 EyePoint Pharmaceuticals, Inc. Antibodies that bind human protein tyrosine phosphatase beta (HPTPbeta) and uses thereof
US7622593B2 (en) * 2006-06-27 2009-11-24 The Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
US20130023542A1 (en) * 2006-06-27 2013-01-24 Aerpio Therapeutics Inc. Human protein tyrosine phosphatase inhibitors and methods of use
US7795444B2 (en) 2006-06-27 2010-09-14 Warner Chilcott Company Human protein tyrosine phosphatase inhibitors and methods of use
US7589212B2 (en) * 2006-06-27 2009-09-15 Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
US8846685B2 (en) 2006-06-27 2014-09-30 Aerpio Therapeutics Inc. Human protein tyrosine phosphatase inhibitors and methods of use
AU2016203254B2 (en) * 2009-01-12 2018-09-13 EyePoint Pharmaceuticals, Inc. Methods for treating vascular leak syndrome
AU2014202211B2 (en) * 2009-01-12 2016-06-02 EyePoint Pharmaceuticals, Inc. Methods for treating vascular leak syndrome
JP5558489B2 (ja) * 2009-01-12 2014-07-23 アケビア セラピューティクス インコーポレイテッド 血管漏出症候群を治療する方法
US9096555B2 (en) 2009-01-12 2015-08-04 Aerpio Therapeutics, Inc. Methods for treating vascular leak syndrome
EP2451279B1 (en) * 2009-07-06 2019-03-13 Aerpio Therapeutics, Inc. Benzosulfonamide derivatives, compositions thereof, and their use in preventing metastasis of cancer cells
US8883832B2 (en) 2009-07-06 2014-11-11 Aerpio Therapeutics Inc. Compounds, compositions, and methods for preventing metastasis of cancer cells
NZ600396A (en) 2009-11-06 2014-08-29 Aerpio Therapeutics Inc Prolyl hydroxylase inhibitors
JP2013539756A (ja) * 2010-10-07 2013-10-28 アエルピオ セラピューティックス インコーポレイテッド 眼球浮腫、血管新生および関連疾患を処置するための組成物および方法
AU2012323856B2 (en) 2011-10-13 2017-05-25 EyePoint Pharmaceuticals, Inc. Methods for treating Vascular Leak Syndrome and cancer
US8999325B2 (en) 2011-10-13 2015-04-07 Aerpio Therapeutics, Inc Treatment of ocular disease
US9962362B2 (en) * 2012-03-29 2018-05-08 Children's Hospital Medical Center Use of small molecule inhibitors targeting EYA tyrosine phosphatase
EP2943487B1 (en) * 2013-01-09 2016-11-16 Gilead Sciences, Inc. 5-membered heteroaryls and their use as antiviral agents
US9725430B2 (en) 2013-01-16 2017-08-08 Children's Hospital Medical Center Use of small molecule inhibitors targeting EYA tyrosine phosphatase
US20150050277A1 (en) 2013-03-15 2015-02-19 Aerpio Therapeutics Inc. Compositions and methods for treating ocular diseases
GB2516561B (en) * 2013-03-15 2016-03-09 Aerpio Therapeutics Inc Compositions, formulations and methods for treating ocular diseases
JP6549140B2 (ja) 2014-02-19 2019-07-24 エアーピオ セラピューティクス インコーポレイテッド Ｎ−ベンジル−３−ヒドロキシ−４−置換ピリジン−２−（１ｈ）−オン
CN106456614A (zh) 2014-03-14 2017-02-22 爱尔皮奥治疗有限公司 HPTP‑β抑制剂
US9539245B2 (en) 2014-08-07 2017-01-10 Aerpio Therapeutics, Inc. Combination of immunotherapies with activators of Tie-2
ES2791340T3 (es) * 2015-05-27 2020-11-03 Kyorin Seiyaku Kk Derivado de urea o sal farmacológicamente aceptable del mismo
CN108290057A (zh) 2015-09-23 2018-07-17 爱尔皮奥治疗有限公司 用tie-2的激活剂治疗眼内压的方法
JP6690282B2 (ja) 2016-02-15 2020-04-28 住友電気工業株式会社 炭化珪素エピタキシャル基板および炭化珪素半導体装置の製造方法
BR112019001206A2 (pt) 2016-07-20 2019-06-25 Aerpio Therapeutics Inc anticorpos monoclonais humanizados que visam ve-ptp (hptp-ss)
WO2020068653A1 (en) 2018-09-24 2020-04-02 Aerpio Pharmaceuticals, Inc. MULTISPECIFIC ANTIBODIES THAT TARGET HPTP - β (VE-PTP) AND VEGF
AU2020264969A1 (en) 2019-04-29 2021-12-09 EyePoint Pharmaceuticals, Inc. Tie-2 activators targeting the schlemm's canal
US11413242B2 (en) 2019-06-24 2022-08-16 EyePoint Pharmaceuticals, Inc. Formulations of Tie-2 activators and methods of use thereof
WO2021086904A1 (en) 2019-10-29 2021-05-06 Aerpio Pharmaceuticals, Inc. Small molecule activators of tie-2
CA3182748A1 (en) * 2020-06-16 2021-12-23 Mannin Research Inc. Ve-ptp inhibitors

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4673641A (en) * 1982-12-16 1987-06-16 Molecular Genetics Research And Development Limited Partnership Co-aggregate purification of proteins
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
ATE380243T1 (de) * 1992-03-13 2007-12-15 Biomerieux Bv Epstein-barr-virus verwandte peptide und nukleinsäuresegmente
US5770565A (en) * 1994-04-13 1998-06-23 La Jolla Cancer Research Center Peptides for reducing or inhibiting bone resorption
US5688781A (en) * 1994-08-19 1997-11-18 Bristol-Myers Squibb Company Method for treating vascular leak syndrome
DK0833934T4 (da) * 1995-06-15 2012-11-19 Crucell Holland Bv Pakningssystemer til human rekombinant adenovirus til anvendelse ved genterapi
AR022303A1 (es) * 1999-01-22 2002-09-04 Lundbeck & Co As H Derivados de piperidina, tetrahidropiridina y piperazina, su preparacion y utilizacion
EP1046715A1 (en) 1999-04-23 2000-10-25 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Interaction of vascular-endothelial protein-tyrosine phosphatase with the angiopoietin receptor tie-2
WO2000065088A2 (en) 1999-04-26 2000-11-02 Amersham Pharmacia Biotech Ab Primers for identifying typing or classifying nucleic acids
IL145941A (en) * 1999-04-28 2007-08-19 Univ Texas Preparations and methods for the treatment of cancer by selective inhibition of VEGF
AU5147700A (en) * 1999-05-19 2000-12-05 Amgen, Inc. Crystal of a lymphocyte kinase-ligand complex and methods of use
ES2252058T3 (es) 1999-08-27 2006-05-16 Sugen, Inc. Mimicos de fosfato y metodos de tratamiento empleando inhibidores de fosfatasa.
US6589758B1 (en) * 2000-05-19 2003-07-08 Amgen Inc. Crystal of a kinase-ligand complex and methods of use
IL154437A0 (en) 2000-09-27 2003-09-17 Procter & Gamble Melanocortin receptor ligands
WO2003082263A1 (en) * 2002-03-29 2003-10-09 Ontogen Corporation Sulfamic acids as inhibitors of human cytoplasmic protein tyrosine phosphatases
US7507568B2 (en) * 2002-09-25 2009-03-24 The Proctor & Gamble Company Three dimensional coordinates of HPTPbeta
US7226755B1 (en) * 2002-09-25 2007-06-05 The Procter & Gamble Company HPTPbeta as a target in treatment of angiogenesis mediated disorders
US20040167183A1 (en) * 2003-02-20 2004-08-26 The Procter & Gamble Company Phenethylamino sulfamic acids
US7588924B2 (en) * 2006-03-07 2009-09-15 Procter & Gamble Company Crystal of hypoxia inducible factor 1 alpha prolyl hydroxylase
AU2007237096C1 (en) 2006-04-07 2012-12-13 EyePoint Pharmaceuticals, Inc. Antibodies that bind human protein tyrosine phosphatase beta (HPTPbeta) and uses thereof
US7589212B2 (en) * 2006-06-27 2009-09-15 Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
US7622593B2 (en) * 2006-06-27 2009-11-24 The Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
US7795444B2 (en) * 2006-06-27 2010-09-14 Warner Chilcott Company Human protein tyrosine phosphatase inhibitors and methods of use
US7769557B2 (en) * 2008-07-01 2010-08-03 Honeywell International Inc. Multi-gas flow sensor with gas specific calibration capability
JP5558489B2 (ja) 2009-01-12 2014-07-23 アケビア セラピューティクス インコーポレイテッド 血管漏出症候群を治療する方法
EP2451279B1 (en) 2009-07-06 2019-03-13 Aerpio Therapeutics, Inc. Benzosulfonamide derivatives, compositions thereof, and their use in preventing metastasis of cancer cells

Also Published As

Publication number Publication date
JP2018048190A (ja) 2018-03-29
KR101179087B1 (ko) 2012-09-07
CA2657107C (en) 2014-01-07
SI2038265T1 (sl) 2015-06-30
JP2013091669A (ja) 2013-05-16
US20120077975A1 (en) 2012-03-29
KR20090024820A (ko) 2009-03-09
NZ574406A (en) 2012-01-12
US8329916B2 (en) 2012-12-11
HK1129387A1 (en) 2009-11-27
JP2016026176A (ja) 2016-02-12
IL196129A (en) 2013-03-24
EP2038265B1 (en) 2015-03-18
EP3293182A1 (en) 2018-03-14
AU2007265454B2 (en) 2011-10-27
CY1116377T1 (el) 2017-02-08
US7795444B2 (en) 2010-09-14
JP2018016657A (ja) 2018-02-01
AU2007265454A2 (en) 2009-04-30
US20080004267A1 (en) 2008-01-03
BRPI0713357A2 (pt) 2012-03-06
CA2657107A1 (en) 2008-01-03
WO2008002570A2 (en) 2008-01-03
EP2592073B1 (en) 2017-08-30
MX2009000289A (es) 2009-03-20
JP5261383B2 (ja) 2013-08-14
US20110212951A1 (en) 2011-09-01
HUE024976T2 (en) 2016-02-29
JP2009542659A (ja) 2009-12-03
PL2038265T3 (pl) 2015-07-31
US8106078B2 (en) 2012-01-31
IL196129A0 (en) 2009-09-22
EP2038265A2 (en) 2009-03-25
AU2007265454A1 (en) 2008-01-03
DK2038265T3 (en) 2015-04-20
PT2038265E (pt) 2015-05-21
WO2008002570B1 (en) 2008-04-17
EP2592073A2 (en) 2013-05-15
WO2008002570A3 (en) 2008-02-14
ES2534392T3 (es) 2015-04-22
JP2015221837A (ja) 2015-12-10
EP2592073A3 (en) 2013-05-29

Similar Documents

Publication Publication Date Title
CO6150140A2 (es) Inhibidores de proteina tirosina fosfatasa humana y metodos de uso
CO6150144A2 (es) Inhibidores de proteina tirosina fosfatasa humana y metodos de uso
AR020551A2 (es) Compuestos macrolidos, composiciones y su uso para la preparacion de medicamentos.
PE20050015A1 (es) Derivados (3-oxo-morfolin-4-il)-fenilamida como inhibidores de factores de coagulacion y compuestos intermediarios en su preparacion
ECSP034865A (es) Resolución óptica de (1-benzilo-4-metilopiperidina-3-il)-metilamina y su uso para la preparación de derivados de pirrolo 2,3-pirimidina como inhibidores de proteina quinasas
PE20050338A1 (es) Compuestos de aminotriazoles como inhibidores de proteina quinasas
PE20151752A1 (es) Amidas heterociclicas como inhibidores de cinasas
AR048641A1 (es) Compuestos de aril- o heteroarilamida ortosustituidos utiles como antago-nistas del receptor de prostaglandinas e2; composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicame
NI201000130A (es) Derivados de urea de tetrahidroquinoxalina, su preparación y su aplicación en terapéutica.
PE20140961A1 (es) Inhibidores macrociclicos de serina proteasas de hepatitis c
AR055150A1 (es) Compuestos de isoindol - imido y composiciones que los comprenden y sus metodos de uso
CO6210721A2 (es) Acilaminopirazoles como inhibidores de fgfr
AR060590A1 (es) Compuestos imidazo
ES2530943T3 (es) Derivados de la cromenona con actividad antitumoral
CO6150164A2 (es) Derivados de 2-metilmorfolina pirido-,pirazo-ypirimido-pirimidina como inhibidores de mtor
AR061134A1 (es) Derivados de tioxantina
AR060591A1 (es) Compuestos imidazo
AR068538A1 (es) Compuesto heterociclico de 5 miembros con actividad supresora de la secrecion de acido
WO2008007122A3 (en) Combinations of pyrazole derivatives for the inhibition of cdks and gsk's
DE602007004740D1 (de) Antibiotische spiroderivate
CO6321266A2 (es) Inhibidores limk2 compuestos de los cuales estan hechos y metodologia de uso
CO5700768A2 (es) Derivados de benzoxazina y sus usos
CR10722A (es) Compuestos heterociclicos y su uso como inhibidores de la glucogeno sintetasa quinasa 3
CO6220950A2 (es) Compuestos heterociclicos compuestos que los comprenden y metodos para su uso
CO5690589A2 (es) Antagonistas de la hormona concentradora de melanina